Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL-1-CD70 CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
NCT07897136Phase 1Not yet recruiting
- Sponsor
- Liping Dou
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLL-1-CD70 CAR-T in acute myeloid leukemia (AML), sponsored by Liping Dou. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CLL-1-CD70 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07897136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897136.